Does Aetna cover Zepbound? It depends on your plan and the reason it is prescribed. Aetna covers Zepbound for weight loss only when your employer’s plan includes weight-loss drugs, and always with prior authorization.[1] It has a separate approval path for moderate to severe obstructive sleep apnea.[1] Many Aetna formularies made Zepbound non-formulary in July 2025, preferring Wegovy, before CVS Caremark said Zepbound would return as a preferred option on October 1, 2026.[2][4]
Prices and program terms checked October 2026. They change often; confirm with the manufacturer or your plan.
Zepbound is tirzepatide; see our tirzepatide profile for how it works.
Aetna and CVS Caremark
Aetna is part of CVS Health, and many Aetna commercial plans use CVS Caremark formularies. That link matters for Zepbound:
- July 1, 2025: CVS Caremark took “a formulary action to prefer Wegovy and remove Zepbound” on its commercial template formularies.[3]
- Aetna’s exception policy, effective the same day, listed Zepbound as non-formulary on several Aetna formularies, with Wegovy as the preferred alternative. Approval of Zepbound required documentation that Wegovy could not be used because of an inadequate response, intolerance or a contraindication.[2]
- October 1, 2026: CVS Caremark said it would add Zepbound back to its commercial formularies “as an additional preferred option” for plan sponsors that choose to cover weight-management drugs.[4] Lilly’s savings page says coverage has been restored on select Caremark formularies.[5]
We could not find a revised Aetna Zepbound exception policy dated after October 1, 2026, so check your own plan’s formulary rather than assuming the change applies to you.
Coverage by reason for treatment
| Reason prescribed | Aetna commercial plans | Aetna Medicare |
|---|---|---|
| Weight management | Only if the plan includes weight-loss drugs; prior authorization[1] | Not covered by Part D; Medicare GLP-1 Bridge for the KwikPen at $50 a month, if eligible[7] |
| Obstructive sleep apnea | Separate tirzepatide pathway with sleep study[1] | Part D plans can cover it under their formulary rules[8] |
| Type 2 diabetes | Not a Zepbound use; Mounjaro is the diabetes brand[6] | Mounjaro through Part D |
| Heart risk reduction | Not a Zepbound indication[6] | Not a Zepbound indication |
Aetna’s 2026 prior authorization criteria
Aetna has several versions of its weight-loss drug policy, and your plan’s sponsor picks which one applies. One 2026 version, the “BMI 35” policy dated April 10, 2026, covers Zepbound, Mounjaro, Wegovy, Saxenda and Foundayo and sets these rules:[1]
Weight reduction (adults):
- Age 18 or older.
- At least 6 months in a comprehensive weight management program with follow-up, before starting the drug.
- A starting BMI of 35 or more.
Obstructive sleep apnea (tirzepatide only):
- Adult with moderate to severe OSA, shown by an apnea-hypopnea index of at least 15 events per hour on a lab or home sleep test.
- Current BMI of 30 or more.
Renewal:
- Weight reduction: at least 3 months on a stable maintenance dose and at least 5% loss of starting weight (or keeping off an initial 5% loss).
- Sleep apnea: a positive response with fewer OSA symptoms.
| Use | Initial approval | Renewal |
|---|---|---|
| Tirzepatide, weight reduction | 8 months | 12 months |
| Tirzepatide, sleep apnea | 6 months | 12 months |
The policy also notes that Zepbound vials and KwikPens are outside its scope because they are sold through Lilly’s LillyDirect program.[1] Other Aetna plans may use lower BMI thresholds that follow the label: 30 or more, or 27 or more with a weight-related condition.[6]
Aetna Medicare
Medicare Part D excludes drugs used for weight loss, so Aetna Medicare drug plans handle Zepbound by indication:
- Sleep apnea: CMS says Zepbound prescribed for moderate to severe OSA stays under Part D, subject to the plan’s formulary and exception process.[8]
- Weight management: since July 1, 2026, eligible members of most Part D and Medicare Advantage drug plans, including Aetna’s, can get the Zepbound KwikPen for $50 a month through the CMS-run Medicare GLP-1 Bridge. Vials and single-dose pens are not covered.[7]
See does Medicare cover Zepbound? for eligibility.
Timeline: Zepbound on Aetna plans
- Before July 2025: Zepbound could be covered on Aetna plans that included weight-loss drugs, with prior authorization.
- July 1, 2025: with CVS Caremark’s formulary change, Aetna listed Zepbound as non-formulary on several formularies and preferred Wegovy. Switching required an exception.[2][3]
- April 10, 2026: Aetna’s updated weight-loss drug policy includes tirzepatide pathways for weight reduction and sleep apnea, alongside Wegovy, Saxenda and Foundayo.[1]
- October 1, 2026: CVS Caremark’s commercial template formularies add Zepbound back as a preferred option for sponsors that cover weight-loss drugs.[4]
Common reasons Aetna denies Zepbound
- The plan excludes weight-loss drugs entirely. No prior authorization can override a benefit exclusion.
- BMI below the plan’s threshold. Under the BMI 35 policy, a BMI of 32 does not qualify for weight reduction, even with other conditions.[1]
- No documented weight program. That policy requires at least 6 months in a comprehensive program before starting.[1]
- Sleep study missing. The OSA pathway needs an apnea-hypopnea index of at least 15.[1]
- Renewal without 5% weight loss. Continuation requires at least 5% loss after 3 months on a stable maintenance dose.[1]
How to check your Aetna coverage
- Log in to your Aetna member website or app and search the drug list for Zepbound. Note the tier and whether it shows PA (prior authorization).
- Call the member services number on your Aetna card. Ask: “Does my plan cover weight-loss drugs? Is Zepbound covered for sleep apnea? Which prior authorization policy applies?”
- Ask your HR benefits team whether your employer adopted the October 2026 Caremark formulary change, since employers can customize.[4]
- Have your prescriber submit prior authorization with your BMI history, weight program records and, for OSA, the sleep study report.
If Aetna denies Zepbound
- Benefit exclusion: if your plan excludes weight-loss drugs, an appeal for weight loss rarely changes that. Ask whether the sleep apnea pathway applies.
- Clinical denial: ask your prescriber to appeal with missing records, such as program participation or BMI documentation.
- Formulary exception: if Zepbound is non-formulary, your prescriber can show why the preferred drug is not suitable.[2]
Paying if Aetna won’t cover it
With commercial insurance that excludes Zepbound, Lilly’s savings card can lower the single-dose pen to as low as $499 a month or the KwikPen to $299 to $449.[5] Paying cash, LillyDirect sells vials and KwikPens for $299 to $449 a month.[9] See Zepbound savings card and does insurance cover Zepbound?
